The pathogenesis of human cancers is thought to involve genetic abnormalities, including alterations in cellular oncogenes and tumor suppressor genes which have regulatory functions in cell proliferation and differentiation (14, 17) . Wild-type p53 has been shown to negatively regulate cell growth, with loss of function appearing to be oncogenic.
Inactivation of the p53 gene-encoded nuclear phosphoprotein can occur through virally encoded oncogenes such as the large T-antigen gene of simian virus 40 and the E6 gene of human papillomavirus or by genetic mechanisms such as deletions, rearrangements, or single-point mutations (17, 32, 34, 37, 43, 45) . Mutations in the p53 gene on chromosome 17p are among the most common genetic alterations in many different human malignancies, including carcinomas of the colon, lung, brain, bladder, and breast (1, 37, 44) . Transgenic mice expressing mutant p53 also have a high incidence of lymphoid tumors, suggesting that p53 may be involved in the development of lymphoid malignancies (33) .
Epstein-Barr virus (EBV), a ubiquitous lymphotropic herpesvirus, is consistently associated with nasopharyngeal carcinoma (NPC), a clonal proliferation of epithelial cells, as well as endemic Burkitt lymphoma (BL) and lymphoproliferations arising in immunocompromised individuals (7, 9, 18, 35, 40, 41, 51) . Mutations in p53 have not been detected in NPC but have been detected in EBV-positive BL tumors and cell lines (4, 11, 16, 19) .
EBV is also associated with lymphoproliferative disease arising in immunosuppressed allograft recipients. These proliferations are thought to initially be polyclonal, with progression to monoclonal or oligoclonal outgrowths (24, 30) . Therefore, to assess the contribution of p53 mutations to this clonal dominance, it is of interest to determine the frequency of p53 mutations in such malignancies. Mutations in p53 were ana-lyzed in biopsy specimens from 29 B-cell lymphomas, including 26 arising in immunocompromised patients, including allograft recipients and patients with AIDS, Wiscott-Aldrich syndrome, and human T-cell leukemia virus type 1 infection, in comparison with three BL samples and four BL cell lines, using single-stranded conformation polymorphism (SSCP) analysis and PCR sequencing. Mutations in p53 were predominantly detected in the BL cell lines and BL biopsy specimens as opposed to lymphomas that develop in immunocompromised patients, suggesting that p53 mutations are not likely involved in the majority of EBV-associated B-cell lymphomas with the exception of BL.
MATERIALS AND METHODS
Tissue and cell lines. The cell lines used, which were maintained in RPMI 1640 with 5 to 10% fetal calf serum, have been described previously (25, 31, 39, 48) . The lymphoma tissue obtained at biopsy and preserved at -70°C has also been previously described (23) ( Table 1 ). Only those tissues that contained predominantly neoplastic cells were used for the molecular studies. The frozen tissues were pulverized and dissolved in 4 M guanidine thiocyanate, and the DNA fractions were extracted twice with phenol and chloroform after dialysis and proteinase K treatment. All specimens were screened for EBV DNA and were compared with dilutions of the Raji cell line to determine the EBV genome copies. The EBV-positive biopsy specimens contained between 1 and >50 copies of EBV, and all were clonal for EBV with the exception of specimens from two allograft recipients, which were biclonal (23, 40) . These results are included in Table 1. SSCP analysis. Primers P1 and P2 (Table 2) were used in a standard PCR to amplify the 2.9-kb fragment of the genomic DNA which contains exons 5 to 8 of the p53 gene (36) . The amplified fragments were purified from a 1% agarose gel after electrophoresis (Geneclean kit; Bio 101, Inc., La Jolla, Calif.). For the SSCP analyses, PCR was performed as previously described (11) . Distinct primer pairs (Table 2) cycles at 94, 55, and 72°C. One microliter of the PCR product was diluted 100-fold, and SSCP analysis was performed as previously described (11) .
PCR sequencing. A portion of the preamplified and purified 2.9-kb fragments of the p53 gene was used in a second asymmetric PCR with primer pairs P3-P4 (exon 5), P5-P6 (exon 6), P7-P8 (exon 7), and P9-P1O (exon 8) (Table 2) (5, 11). For exons 4 and 9, a standard PCR was performed as described above from the genomic DNA, using primer pairs P1 -P12 and P9-P2, respectively (Table 2) (5, 11). The amplified fragments were purified (Majic PCR Prep; Promega Corp., Madison, Wis.). For sequence analysis, the preamplified fragments containing exons 4 and 9 were used in a second asymmetric PCR with primer pairs P1 1-P12 (exon 4) and P9-P2 (exon 9) ( amide, the gel was dried and exposed to Kodak XAR film overnight.
Detection of allelic loss. Differential PCR was performed with the gamma interferon reference gene as previously described (36) . Amplification of sequences in exons 5, 7, and 8 of the p53 gene was performed in conjunction with the amplification of an 84-bp sequence within the gamma interferon gene. After electrophoresis and ethidium bromide staining of the PCR products, the degree of amplification was determined by densitometric analysis of the negatives.
Chromosome 17p has a variable number of tandem repeats; therefore, oligonucleotide primers which span the repeated pYNZ22 region were used (28) . Amplification and analysis were performed as previously described (12, 28) .
The known polymorphism in exon 4 within an AccII site was also used to determine the number of alleles within a tissue (5) . The polymorphism was detected by direct sequencing and/or by restriction digestion with AccII. A fraction of the purified exon 4 PCR product from the procedure described above was digested with AccII and subjected to electrophoresis on an 12% polyacrylamide gel. A 259-bp fragment represented allele 1, and 160-and 99-bp fragments represented allele 2 (12) . RESULTS PCR analysis of p53. The DNA samples were screened for p53 deletions by PCR. A 2.9-kb fragment of p53 (primers P1 and P2 [ Table 2 ]) including the coding sequences for exons 5 to 8 was amplified along with fragments containing exons 4 and 9, with successful amplification being indicative of intact coding sequences. The 2.9-kb fragment was successfully amplified from all samples except the P3HR1 cell line. Differential PCR was used to analyze the P3HR1 cell line for further deletions of exons 5, 7, and 8. Amplification of exons 5, 7, and 8 along with the gamma interferon gene as a control was performed. All three exons were present, suggesting that the P3HR1 cell line contains a deletion or mutation of sequences around primers P1 and/or P2 as well as the previously characterized mutation in exon 5 (data not shown) (16) .
Detection of p53 mutations by SSCP analysis and PCR. Point mutations can significantly alter p53 function, with more than 98% of all mutations in p53 detected in exons 5 to 8 (27, 37) . Therefore, SSCP analysis was used to screen the samples for sequence changes in exons 5 to 8. With this technique, radiolabeled PCR products when denatured and allowed to renature will assume intramolecular secondary structures unique for that sequence. SSCP analysis has successfully detected point mutations in the p53 gene as well as the ras gene family and the neurofibromatosis type I gene (6, 11, 12, 13, 38) .
For SSCP analysis, exons 5 to 8 were amplified from the 2.9-kb fragment and subsequently subjected to electrophoresis under nondenaturing conditions. To confirm the sensitivity of the SSCP, controls included known examples of both normal and single-point mutations for the exon in question. In samples with mutations in p53, multiple abnormal migration patterns and extra bands were consistently detected when compared with the normal control samples. Of the 33 samples, abnormal migration patterns were detected in seven samples (Table 3) .
To confirm the SSCP results, the abnormal specimens as well as a sampling of normal specimens were sequenced. Abnormal migration was not detected by SSCP analysis in exon 5, and sequencing confirmed this finding (Table 3) .
Sequence analysis of exon 6 detected a polymorphism on one allele in the posttransplant lymphoma (PTL), T594, with a transition from CGA to CGG in codon 213 (Fig. IA) Fig. 2A and  3A) . Multiple additional bands were detected by SSCP in samples with a single mutation in p53 (Fig. 2) . Sequence analysis confirmed the previously described base changes in codons 238 and 248 in the Louckes and Namalwa BL cell lines, respectively ( Fig. 2B and 2C ; (10) .
In the BL biopsy specimens, Burkitt had a transition from CGG to CAG in one allele of codon 248, resulting in a change of an arginine to glutamine ( Fig. 3B ; Table 4 ). The identical mutation was detected in the Namalwa cell line, and the two samples had identical abnormal migration patterns (Fig. 3A) .
Coo had a transition from AAC to GAC in one allele of codon 239, resulting in a change of an asparagine to an aspartic acid ( Fig. 3C ; Table 4 ). Blou had a transversion from TCC to ACC in codon 241 of one allele, with a subsequent amino acid change of serine to threonine ( Fig. 3D ; Table 4 ). All of the BL cell lines and samples had mutations within a specific region of exon 7, confirming the previous observation that p53 mutations are clustered (4) . SSCP analysis of exon 8 revealed abnormal banding in one of the AIDS-related lymphomas (ARL), Cas three normal samples in exon 8, Namalwa, Ber, and Com, and one known mutant control, CNE-1, which has a mutation in codon 280 (Fig. 4A ). Sequencing detected a point mutation in one allele of codon 278 with a transition from CCT to CIT and a subsequent change in the amino acid from proline to leucine ( Fig. 4B ; Table 4 ).
In all cases, sequence analysis confirmed the normal and abnormal SSCP patterns. In reconstruction experiments, a mutation in p53 in 5% of the DNA produced an abnormal banding pattern by SSCP (11) . Sequence analysis of mixtures of mutant and normal DNA in the same sample detected mutations with 20% mutant DNA (11) . All samples with mutations were sequenced several times from different asymmetric amplifications to control for PCR-introduced mutation during amplification.
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detected in a few sarcomas (47) . Sequence analysis of exons 4 and 9 in 25 of the specimens analyzed in this study did not detect any mutations (Table 3) . Tables 3 and 4 summarize the p53 mutations detected in B-cell lymphomas and BL cell lines. Alterations in p53 were not detected in lymphomas arising under immunosuppression, while they occurred at high frequency in BL and BL cell lines. In all lymphoma samples, the changes were point mutations leading to amino acid changes, with retention of the wild-type allele.
Detection of allelic loss. In a recent study of bone and soft tissue sarcomas, allelic loss of p53 was detected with the retention of a wild-type p53 allele (47) . This finding suggested that allelic loss at the p53 locus with a possible decrease in the p53 gene product could confer a growth advantage and contribute to oncogenesis. Therefore, to determine whether allelic loss had occurred in the lymphoma samples with wild-type p53, the specimens were analyzed by several methods, including differential PCR and sequence analysis of known polymorphic regions.
Differential PCR was performed with the gamma interferon gene as a reference gene in comparison with four BL cell lines previously reported to contain one or two p53 alleles. Comparison of the intensities of exons 5, 7, and 8 with that of the reference gene confirmed allelic loss in the BL cell lines, Namalwa and P3HRI, and the presence of two alleles in the Raji cell line (Table 5 ) (16) . Differential PCR with the gamma interferon reference gene did not indicate a loss of p53 sequences in the PTL, ARL, or BL samples (Table 5) .
To confirm this determination of the number of alleles, a polymorphism within exon 4 which encompasses an AccII site was analyzed by sequencing and AccII digestion. AccII digestion identified two polymorphic alleles in 10 of 24 samples, while 14 of the samples were not polymorphic at this site (Table 5 ). However, 4 of the 14 nonpolymorphic samples (T594, Cas, Blou, and Coo) had mutations in the p53 coding sequence, with detection of both the mutant and normal sequences (Table 5 ). This result indicates the presence of both the wild-type and mutant alleles and confirmed the differential PCR analyses. The Raji cell line, which contains two alleles, was polymorphic at the AccII site, and both mutant and normal sequences were detected at the site of mutation in exons 6 and 7 ( Fig. 1 and 2 ; Table 5 ).
An additional approach analyzed a region on chromosome 17p, pYNZ22, which contains a variable number of sequence repeats (28 (27, 37) . Several previous studies have detected p53 mutations in examples of BL and ARL, with detection of p53 mutations in both EBV-positive and EBV-negative samples (2, 4, 16, 19) . The data presented here confirm that the p53 mutations in BL occur within a specific region in exon 7, regardless of the presence of EBV or geographic location (4, 19) . The progression to neoplasia in BL seems to involve not only the c-myc translocation but also p53 inactivation (8) . In the AIDS lymphomas analyzed here, a single EBV-positive specimen contained an altered p53 gene.
In many tumors previously studied, p53 mutations were detected in the absence of a normal allele (37, 45) . However, in all of the samples analyzed in this study, a wild-type allele was retained. Similarly, in a series of EBV-negative non-Hodgkin's B-cell lymphomas, mutations were detected in approximately 20% of the samples, with retention of the wild-type allele in all but one (29) . These results suggest that in lymphomas, the transdominant inactivation of wild-type p53 by mutant forms of p53 can contribute to the emergence of a malignant clone in vivo.
The detection of p53 mutations in all four BL cell lines raises the possibility that p53 mutations give a growth advantage in cell culture or arise during passage. Notably, the mutation detected in P3HR1 p53 is different from the mutation in the parent cell line Jijoye, and the P3HR1 and Raji cell lines cultured in our laboratory contained mutations in addition to those previously described (16) . In this study, a deletion and/or mutation in the P1 and/or P2 region of P3HR1 and an additional mutation in codon 234 of exon 7 of Raji as well as the mutation in codon 213 were detected (10 (11, 12) .
In contrast to the development of p53 mutations in BL or ARL, although clonal or oligoclonal PTL develops from an initial polyclonal proliferation, mutations in p53 were not detected in any of the PTL samples analyzed here. This suggests that p53 mutations do not contribute to the development of these tumors and the emergence of a dominant clone, similar to the absence of p53 mutation in NPC (11, 40) . The fact that BL has p53 alterations while NPC and PTL do not, even though EBV is associated with all three diseases, suggests that EBV viral gene expression may influence the selection for p53 mutations. EBV gene expression is known to be different in BL compared with NPC and PTL. In BL, only the EBV nuclear antigen EBNAI is thought to be expressed, while in NPC, EBNA1, the latent membrane proteins LMP1 and LMP2, and a gene encoded by the BamHI A fragment are consistently expressed (15, 20, 26, 42, 49) . Recent data also indicate that EBNA2 and LMP1 are expressed in lymphoproliferative disorders which develop during immunosuppression (21, 46, 50) . As LMP1 expression has been shown to suppress apoptosis or programmed cell death in human B cells, it is possible that LMPI or another EBV gene product expressed in the PTLs and NPC may indirectly suppress p53 function, thereby altering the negative growth-regulatory properties of p53 (22) .
